Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Correlation Of Serum Level Of Squamous Cell Carcinoma Antigen With Severity Of Cutaneous Psoriasis, Assessed Using The Simplified Psoriasis Index.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Correlation Of Serum Level Of Squamous Cell Carcinoma Antigen With Severity Of Cutaneous Psoriasis, Assessed Using The Simplified Psoriasis Index.

Related Experiment Video

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Correlation of serum level of squamous cell carcinoma antigen with severity of cutaneous psoriasis, assessed using the simplified psoriasis index.

D Henry¹, A Alkhars¹, M Samimi²

¹Dermatology Department, Centre Hospitalier Régional Universitaire, Tours, France.

Annales De Dermatologie Et De Venereologie

|February 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Serum Squamous Cell Carcinoma Antigen (SCCA) levels correlate with psoriasis severity, as measured by the Simplified Psoriasis Index (SPI). This finding, using a commercial kit, suggests SCCA may serve as a valuable biomarker for assessing psoriasis activity.

Keywords:

Biomarker Psoriasis Psoriasis Assessment Severity Index (PASI)Squamous cell carcinoma antigen (SCCA)

More Related Videos

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Related Experiment Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

Dermatology
Biochemistry
Immunology

Background:

Squamous cell carcinoma antigen (SCCA) is implicated in both squamous cell carcinoma progression and psoriasis pathogenesis.
Previous studies indicated a link between psoriasis severity and serum SCCA levels, primarily SCCA2, using non-commercial assays.
This study investigated the correlation between serum SCCA and psoriasis severity using a commercial assay and the Simplified Psoriasis Index (SPI).

Purpose of the Study:

To examine the correlation between serum SCCA levels, measured by a commercial kit, and psoriasis severity assessed using the Simplified Psoriasis Index (SPI).
To evaluate SCCA's potential as a biomarker for psoriasis severity.

Main Methods:

A prospective, non-interventional, single-centre study was conducted over 18 months.

Serum SCCA levels and psoriasis severity scores (proSPI-s, proSPI-p, proSPI treatment score) were measured simultaneously.

Secondary endpoints included Dermatology Life Quality Index (DLQI) and inflammation markers (CRP, neutrophil-to-lymphocyte ratio).

Main Results:

Serum SCCA levels showed a significant correlation with proSPI-s at baseline and follow-up (Spearman r = 0.686 and r = 0.674, p < 0.0001).
SCCA levels also correlated with proSPI-p and DLQI, indicating a link with psychosocial impact and quality of life.
No significant correlation was found between serum SCCA levels and C-reactive protein or neutrophil-to-lymphocyte ratio.

Conclusions:

This study establishes the first correlation between serum SCCA levels and proSPI-s using a commercially available kit.
The findings suggest that SCCA can be utilized as a biomarker for assessing psoriasis severity.
SCCA measurement offers a potentially accessible method for monitoring psoriasis activity.